MediGene Appoints Dr Hans Joachim Bochtler as Vice President Clinical Research & Development

Corporate news announcement processed and transmitted by Hugin ASA.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------

Martinsried/Munich, September 15, 2008. MediGene AG (Frankfurt, Prime
Standard: MDG) is pleased to announce the appointment of Hans Joachim
Bochtler, MD, as Vice President Clinical Research & Development. Dr
Bochtler succeeds Dr Axel Mescheder, who was appointed Executive
Board Member for Research & Development in May 2008. Dr Bochtler is a
physician with long-standing management experience in clinical
research and development at both international pharmaceutical and
biotechnology companies. Most recently, he served as Chief Scientific
Officer of Fresenius Biotech GmbH.

Dr Axel Mescheder, MediGene's Executive Board Member for Research &
Development, commented: "We are very pleased to have secured such a
highly qualified expert for MediGene AG in Dr Bochtler. As a seasoned
oncology specialist with comprehensive international experience in
the development and approval of drugs, he is an ideal fit for this
position. Dr Bochtler is a physician and beyond his R&D expertise he
also has experience in sales and marketing. We believe that this
combination of skills provides an ideal background qualification for
the advancement of MediGene's innovative drug candidates to
marketable and competitive products."

Dr Hans Joachim Bochtler studied Biology in Ulm and Human Medicine in
Göttingen, Ulm, and Munich. After working as an assistant physician
at Munich's University Hospital Rechts der Isar in 1993, he moved on
to the biopharmaceutical industry, where he worked as Medical Advisor
Oncology at Bristol-Myers Squibb GmbH & Co. KgaA in Munich for three
years. He returned to Bristol-Myers Squibb in 1999 after holding
positions as Medical Marketing Manager at Smith Kline Beecham Pharma
GmbH and Head of Clinical Research at Amgen GmbH, both in Munich. At
Bristol-Myers Squibb, he served as Director Medical Oncology and
subsequently as Director Sales & Marketing in the oncology division.
Since 2005, Dr Bochtler had been Head of Global Scientific & Medical
Affairs / Chief Scientific Officer at Fresenius Biotech GmbH in
Munich. He will take up his position at MediGene on September 15,
2008

Dr Bochtler, the new Vice President Clinical Research & Development
at MediGene, said: "I am looking forward to my new job at MediGene
very much. The company has a very attractive pipeline and I am
excited to help the team tap into the full potential of its research
and development projects. MediGene is the first German biotech
company with marketed products and it is my intention to assist in
further extending this lead."

This press release contains forward-looking statements representing
the opinion of MediGene as of the date of this release. The actual
results achieved by MediGene may differ significantly from the
statements made herein. MediGene is not bound to update any of these
forward-looking statements. MediGene® is a trademark of MediGene AG,
this trademark may be owned or licensed in select locations only.

- ends -

MediGene AG is a publicly listed (Frankfurt, Prime Standard: MDG)
biotechnology company located in Martinsried/Munich, Germany, with
subsidiaries in Oxford, UK and San Diego, USA. MediGene is the first
German biotech company to have drugs on the market, which are being
distributed by partner companies. MediGene has several drug
candidates in clinical development, some of which with an individual
annual peak sales potential exceeding 1 billion ¤. Moreover, the
company has projects in research and pre-clinical development and
possesses innovative platform technologies. MediGene focuses on the
research and development of novel drugs for the treatment of cancer
and autoimmune diseases.

Contact MediGene AG
E-mail: investor@medigene.com
Fax:++49 - 89 - 85 65 - 2920
Julia Hofmann / Dr. Nadja Wolf, Public Relations, Tel.: ++49 - 89 -
85 65 - 3324
Dr. Georg Dönges, Investor Relations, Tel.: ++49 - 89 - 85 65 - 2946

--- End of Message ---

MediGene AG
Lochhamer Strasse 11 Martinsried / München Germany

WKN:
502090; ISIN: DE0005020903 ;
Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in
Bayerische Börse München,
Freiverkehr in Börse Düsseldorf, Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr
in Niedersächsische Börse zu Hannover,
Geregelter Markt in Frankfurter Wertpapierbörse;
Copyright © Hugin AS 2008. All rights reserved.